Stage III Prostate Cancer Clinical Trial
Official title:
A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers
Verified date | November 2021 |
Source | University of Southern California |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer. Recombinant EphB4-HSA fusion protein may block an enzyme needed for tumor cells to multiply and may also prevent the growth of new blood vessels that bring nutrients to the tumor. Giving recombinant EphB4-HSA fusion protein before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
Status | Terminated |
Enrollment | 2 |
Est. completion date | November 15, 2021 |
Est. primary completion date | January 28, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information - NOTE: HIPAA authorization may be included in the informed consent or obtained separately - Eastern Cooperative Oncology Group (ECOG) performance status of =< 1 within 14 days prior to being registered for protocol therapy - Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuation - Females of childbearing potential must have a negative pregnancy test within 7 days prior to being registered for protocol therapy - NOTE: Subjects are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal - Females must not be breastfeeding - Cohort A - T2, Transitional cell carcinoma (TCC) muscle invasive bladder cancer, (patients who are cisplatin ineligible, decline neoadjuvant and/or ineligible for neoadjuvant chemotherapy); must have histological proof of T2, muscle-invasive transitional cell carcinoma of the bladder with no evidence of metastatic; patient with any degree of fixation of the pelvic sidewall are not eligible - Cohort B - Prostate cancer (Gleason 7 or less); must have histological proof of Gleason =< 7 with no evidence of metastatic disease (patient with any degree of extra-prostatic capsule extension are not eligible - Cohort C - Renal cell carcinoma (> pT1b); must have radiologic suspicion or histological proof of clear cell renal cell carcinoma >= 4 cm with no evidence of metastatic disease; patient with any degree of tumor extension into the renal vein are not eligible; patients must be candidates for contrast-enhanced ultrasound (CEUS) imaging and agree to undergo this additional imaging technique - Patients must be willing to undergo a biopsy of the cancerous tissue if one was not taken within the previous year, prior to drug initiation if tumor block is not available; biopsy must be done within 14 days of first planned drug dose - Patients must be willing to undergo a radiologic scan (computed tomography [CT] or magnetic resonance imaging [MRI], depending on organ involved) after last drug dose and prior to minimally-invasive surgery - Eligible for: - Cohort A: Robot-assisted radical cystectomy (RARC) as per the attending urologist - Cohort B: Robot-assisted radical Nephrectomy (RARN)/robot-assisted partial nephrectomy (RAPN) as per the attending urologist - Cohort C: RAPN as per the attending urologist - No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancers for which the patient has been disease-free for at least 5 years - No treatment with any investigational agent within 30 days prior to being registered for protocol therapy - No prior systemic chemotherapy for transitional cell carcinoma of the bladder (prior intravesical therapy is allowed); any other prior chemotherapy must have been completed > 5 years prior to initiation of therapy - Prior radiation therapy is allowed provided that no radiation therapy was administered to the urinary bladder - NOTE: No radiation therapy within 28 days prior to being registered for protocol therapy; laboratory values must be obtained within 14 days prior to being registered for protocol therapy - Total bilirubin < 2.0 X upper limit of normal (ULN) - Aspartate aminotransferase (AST) =< 2.5 X ULN - Alanine aminotransferase (ALT) =< 2.5 X ULN - Serum Creatinine < 2.5 X ULN - Absolute neutrophil count (ANC) > 1.5 X K/mm^3 - Platelets > 100 K/mm^3 - International normalized ratio (INR) =< 1.2 - There are currently no known concomitant medications that must be discontinued prior to administration of registration on study and for the duration of sEphB4-HSA - No clinically significant infections as judged by the treating investigator - No pleural or pericardial effusion of any grade - No uncontrolled angina, congestive heart failure or myocardial infraction (MI) within 6 months prior to registration on study - No diagnosed arrhythmias - No abnormalities on pre-entry electrocardiogram, obtained within 28 days prior to being registered on study - No history of diagnosed congenital bleeding disorders (e.g., von Willebrand's disease) - No abnormalities no history of diagnosed acquired bleeding disorders within one year (e.g., acquired anti-factor VIII antibodies) of registration on protocol therapy - No abnormalities no history of ongoing or recent (less than or equal to 3 months of registration on protocol therapy) significant gastrointestinal bleeding - No ongoing anti-coagulation and/or anti-platelet therapies allowed - Patients with diagnosed uncontrolled hypertension (> 150/90 mmHg) are to be excluded - Patients with hypertension controlled with medications are allowed - No evidence of gross hematuria - No evidence of hydronephrosis - No evidence of a history of a stroke or myocardial infarction within the last 6 months prior to study enrollment - No evidence of a history of wound healing complications prior to study enrollment |
Country | Name | City | State |
---|---|---|---|
United States | USC / Norris Comprehensive Cancer Center | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
University of Southern California | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility, defined as the percentage of patients completing at least 3 doses of drug therapy without dose limiting toxicities (DLTs) and who are able to undergo minimally-invasive surgery as planned | Feasibility is defined for the purpose of this study as >= 90% of patients completing at least 3 doses of drug therapy without DLTs and are able to undergo minimally-invasive surgery as planned. | Up to 30 days after the last dose of sEphB4-HSA | |
Primary | Incidence of adverse events graded according to CTCAE version 4 or the Clavien-Dindo classification | All observed adverse events and complications will be summarized in terms of type (organ affected or laboratory determination such as absolute neutrophil count), severity, and time of onset. Tables will be created to summarize these adverse events and complications, overall, by disease cohort, and by phase (neoadjuvant, during surgery, within 30 days post-operative, and days 31-90 post-operative). | Up to 90 days post-surgery | |
Secondary | Complete pathologic response defined as no residual evidence of invasive disease at the time of cystectomy or nephrectomy | Pathologic response rates will be calculated and 90% confidence intervals will be constructed. | At the time of surgery | |
Secondary | Radiologic response as evaluated by Response Evaluation Criteria in Solid Tumors version 1.1 | Radiologic response rates will be calculated and 90% confidence intervals will be constructed. | Up to 30 days post-surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02217709 -
Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT02846870 -
Visually Enhanced Education About Prostate Cancer
|
N/A | |
Completed |
NCT00103194 -
Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer
|
Phase 2 | |
Completed |
NCT01385059 -
Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer
|
Phase 2 | |
Terminated |
NCT00536991 -
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00074022 -
GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04589468 -
Researching the Effect of Exercise on Cancer
|
N/A | |
Active, not recruiting |
NCT01823562 -
Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery
|
Phase 1 | |
Active, not recruiting |
NCT01923506 -
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
|
Phase 1 | |
Recruiting |
NCT02605226 -
Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer
|
N/A | |
Completed |
NCT00589472 -
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02278185 -
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
|
Phase 2 | |
Completed |
NCT01117935 -
Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer
|
N/A | |
Completed |
NCT01731912 -
Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer
|
N/A | |
Withdrawn |
NCT00996749 -
Omega-3 Fatty Acids in Treating Patients With Advanced Prostate Cancer
|
N/A | |
Completed |
NCT01656304 -
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
|
Phase 2 | |
Recruiting |
NCT03880422 -
Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
|
N/A | |
Completed |
NCT02048150 -
Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer
|
Phase 1 | |
Withdrawn |
NCT01555632 -
Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy
|
N/A | |
Completed |
NCT00956163 -
Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients With Prostate Cancer
|
Phase 0 |